Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Study Identifier:
APL-22
ClinicalTrials.gov Identifier:
NCT06484868
EudraCT Identifier:
N/A
Study Contact Information:
+3905212791 or [email protected]
Recruiting

Study Details

Medical Condition
  • Partial Lipodystrophy
Study Drug
  • Drug: Metreleptin
Date
Feb 2024 - Feb 2028
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 12+ years
Requirements Information
Healthy Volunteers
No

Protocol Summary

This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy

Study Locations

Location
Status
Location
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez
Lille, France
Status
Recruiting
Location
Hopital Pitie-Salpetriere
Paris, France
Status
Recruiting
Location
Hôpital Saint-Antoine
Paris, France
Status
Recruiting
Location
Centre Hospitalier Lyon-Sud
Pierre-Bénite, France
Status
Recruiting
Location
Charite-Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)
Berlin, Germany
Status
Recruiting
Location
Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin
Ulm, Germany
Status
Not yet recruiting